Lu Jianyun, Qin Guizhi, Huang Jinhua, Li Suo, Zhao Jing, Xiang Yaping, Chen Jing, Zuo Chengxin, Yang Shengbo, Tna Lina
Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011 Nov;36(11):1102-5. doi: 10.3969/j.issn.1672-7347.2011.11.012.
To evaluate the short-term efficacy and safety of propranolol for problematic infantile hemangiomas.
Oral propranolol was administered to 68 infants with heamngiomas diagnosed by clinical evaluation and adjuvant examination at 1.0~2.0 mg per kilogram of body weight per day, divided to 2 or 3 times. The patients revisited once a month. The changes of the tumor size, texture, and color were monitored and recorded at a regular interval.The adverse effects after medication were observed and managed accordingly.The short-term results were evaluated using a 4-grade system.
All the 68 infants were followed up for 3-13 months, except that 1 infants combined with other diseases and 4 withdrew.The overall response was Scale 1 in 8 infants, Scale II in 13, Scale III in 29, and Scale IV in 13. No serious adverse effects were seen, but none cured entirely as well.
Oral propranolol is safe and effective for infantile heamngioma with good short-term result. It could be used as the primary drug for problematic infantile hemangiomas at the rapid growth stage of hemangiomas.
评估普萘洛尔治疗婴幼儿血管瘤的短期疗效及安全性。
对68例经临床评估及辅助检查确诊为血管瘤的婴幼儿口服普萘洛尔，剂量为每日每千克体重1.0~2.0毫克，分2至3次服用。患者每月复诊一次。定期监测并记录肿瘤大小、质地及颜色的变化。观察用药后的不良反应并进行相应处理。短期疗效采用四级评分系统进行评估。
68例婴幼儿中，除1例合并其他疾病及4例失访外，其余均随访3至13个月。总体疗效：1级8例，Ⅱ级13例，Ⅲ级29例，Ⅳ级13例。未见严重不良反应，但也无完全治愈者。
口服普萘洛尔治疗婴幼儿血管瘤安全有效，短期效果良好。可作为血管瘤快速增殖期婴幼儿血管瘤的一线用药。
